“If you take away funding from research and development, especially for diseases with pandemic potential, those programs will be delayed. We lose time, and some of that time can’t be recovered later with more funding.” Anand Ekambaram has spent more
Morepen Laboratories has secured a multi-year Contract Development and Manufacturing Organisation (CDMO) mandate valued at approximately ₹825 crore (USD 91 million) from a global pharma company. The company stated that supplies under the agreement are expected to begin within four
Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organisation (CDMO) and multimodality biosafety testing provider, has joined the California Institute for Regenerative Medicine (CIRM) Industry Resource Partner (IRP) Program. The announcement confirms that the company will
On February 20, the U.S. Supreme Court delivered one of the most consequential trade rulings in decades. In a 6–3 decision, the justices held that President Trump had no authority under the International Emergency Economic Powers Act (IEEPA) to impose
Recipharm, a global CDMO, has announced a strategic investment to strengthen its high-potency oral solid dose (OSD) capabilities at its Leganés site in Spain. The new high-potency clinical and pilot capabilities are scheduled to be operational by the end of
Cellares, an Integrated Development and Manufacturing Organization (IDMO), has expanded its partnership with the University of Wisconsin (UW) School of Medicine and Public Health to support the clinical production and regulatory advancement of the university’s CRISPR-edited GD2 CAR-T investigational therapy.
VivaMed BioPharma has entered into a collaboration with Syngene International, a contract research development and manufacturing organization (CRDMO), to strengthen its AI-powered drug discovery and validation infrastructure. The partnership is designed to integrate VivaMed’s AI-derived therapeutic hypotheses with Syngene’s preclinical
Cross-border licensing deals between Greater China-based biopharmaceutical companies and global drugmakers reached an unprecedented $137.7 billion in 2025, a nearly tenfold increase from 2021’s $13.9 billion, according to China-based data provider PharmCube. Industry analysts now predict 2026 will surpass that
MGS, a contract development and manufacturing organization (CDMO), has introduced a new manufacturing facility in Richfield, Wisconsin. The 300,000-square-foot site was developed to support a global pharmaceutical partner’s expanding drug delivery platform and to meet increasing demand for high-volume manufacturing
In an industry where the wrong manufacturing partnership can derail a drug program, and the right one can accelerate it, biotech leaders face mounting pressure to make smarter, faster decisions about their CDMOs. But are they asking the right questions?
